Synapse - Works

Results (13087)

Secondary graft-versus-host disease (GVHD) prophylaxis with oral proteasome inhibitor ixazomib is associated with low incidence of recurrent, late acute and chronic GVHD and facilitated calcineurin inhibitor taper within the first year post allogeneic stem cell transplantation

Meeting Abstract

Rodriguez, N.; Lee, J.; Flynn, L.; Murray, F.; Devlin, S.; Izquierdo, C. S.; Cho, C.; Dahi, P. B.; Giralt, S. A.; Sauter, C. S.; more...
Blood (2020)

Fulltext@MSK | Save

Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era

Meeting Abstract

Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
Blood (2020)

Fulltext@MSK | Save

COVID-19 in patients (pts) with chronic myeloid leukemia (CML): Results from the international CML foundation (iCMLf) CML and COVID-19 (CANDID) study

Meeting Abstract

Rea, D.; Mauro, M. J.; Cortes, J. E.; Jiang, Q.; Pagnano, K. B.; Ongondi, M.; Kok, C. H.; Evans, N.; Hughes, T. P.; International CML Foundation
Blood (2020)

Fulltext@MSK | Save

Prognostic factors for North American adult T cell leukemia lymphoma: Defining risk groups using a four-point score prognostic system

Meeting Abstract

Rahman, S.; Soto, A. A.; Qunaj, L.; Ye, K.; Pradhan, K.; Thakkar, A.; Cui, Z.; Meron, M. K.; D'Aiello, A.; Lombardo, A.; more...
Blood (2020)

Fulltext@MSK | Save

Analysis of the global methylation profile of accelerated and blast phase myeloproliferative neoplasms and its association with response to decitabine-based therapy

Meeting Abstract

Rampal, R. K.; Yang, Q.; Koche, R. P.; McGovern, E.; Famulare, C.; Weinberg, R. S.; Mascarenhas, J.; Levine, R. L.; Hoffman, R.; Figueroa, M. E.
Blood (2020)

Fulltext@MSK | Save

LSD1 inhibitor CPI-482 shows efficacy and prolongs survival in mouse models of AML and post-MPN AML in the context of constitutive JAK-STAT pathway activation

Meeting Abstract

Rampal, R. K.; McGrath, J. P.; Krishnan, A.; Li, B.; Xiao, W.; Nikom, D.; Wang, J.; Levine, R. L.; Trojer, P.
Blood (2020)

Fulltext@MSK | Save

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial: Dose optimization efficacy update and expansion phase initial results

Meeting Abstract

Pro, B.; Brammer, J. E.; Casulo, C.; Jacobsen, E.; Mead, M.; Mehta-Shah, N.; Zain, J. M.; Zinzani, P. L.; Lustgarten, S.; Youssoufian, H.; more...
Blood (2020)

Fulltext@MSK | Save

Association of baseline and postinfusion biomarkers with safety and efficacy endpoints in patients treated with orvacabtagene autoleucel (orva-cel; JCARH125) in the phase 1/2 evolve study (NCT03430011)

Meeting Abstract

Piasecki, J.; Devries, T.; Radhakrishnan, A.; Li, Y.; Heipel, M.; Fox, B. A.; Beckett, V.; Stirner, M. C.; Conte, K.; Doerr, T.; more...
Blood (2020)

Fulltext@MSK | Save

Characteristics and outcomes of newly diagnosed acute myeloid leukemia patients receiving venetoclax combinations vs other therapies: Results from the AML real world evidence (ARC) Initiative

Meeting Abstract

Pollyea, D. A.; Stahl, M.; Talati, C.; Asghari, H.; Lai, C.; Abedin, S.; Zeidner, J. F.; Muluneh, B.; Xavier, M.; Edwards, W.; more...
Blood (2020)

Fulltext@MSK | Save

A Phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated al amyloidosis (SWOG S1702; NCT#03499808)

Meeting Abstract

Parker, T. L.; Rosenthal, A.; Sanchorawala, V.; Landau, H. J.; Campagnaro, E.; Kapoor, P.; Neparidze, N.; Hagen, P.; Sarosiek, S.; Scott, E. C.; more...
Blood (2020)

Fulltext@MSK | Save